Financial Performance - The company's revenue for Q3 2023 was ¥2,984,352,397.45, a decrease of 14.28% compared to ¥3,481,328,298.92 in the same period last year[8] - Net profit attributable to shareholders for Q3 2023 was ¥117,780,192.97, down 25.03% from ¥157,107,051.58 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥106,595,479.19, reflecting a decline of 25.65% compared to ¥143,372,114.16 in the previous year[8] - Basic earnings per share for Q3 2023 were ¥0.0595, down 25.06% from ¥0.0794 in the same quarter last year[8] - The net profit for the current period is 875,142,530.13, a decrease of 34.7% compared to 1,342,581,873.08 in the previous period[30] - Operating profit for the current period is 1,118,574,829.98, down from 1,818,006,436.61, reflecting a decline of 38.5%[30] - Total comprehensive income for the current period is 931,186,872.20, down from 1,553,326,463.12, representing a decline of 40.0%[30] - The company reported a basic earnings per share of 0.2550, down from 0.3621, reflecting a decrease of 29.5%[30] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥970,589,635.32, a significant drop of 48.61% from ¥1,888,672,141.44[8] - The net cash flow from operating activities decreased by 48.61% to ¥970,589,635.32 compared to ¥1,888,672,141.44 in the previous period, primarily due to a decline in sales scale[16] - The net cash flow from investing activities showed a significant decrease of 1620.00%, amounting to -¥409,598,318.92, attributed to increased long-term asset purchases and a reduction in redeemed financial products[16] - The net cash flow from financing activities increased by 47.90% to -¥464,731,600.04, mainly due to an increase in financing scale during the reporting period[16] - Cash flow from operating activities generated a net amount of 970,589,635.32, compared to 1,888,672,141.44 in the previous period, indicating a decrease of 48.6%[33] - Cash inflow from investment activities is 5,213,786,313.09, down from 6,399,652,310.89, indicating a decline of 18.5%[33] - The company’s cash flow from financing activities totaled 7,274,106,554.18, an increase from 6,965,012,937.74, reflecting a growth of 4.4%[33] - Net cash flow from financing activities improved to -$464,731,600.04 from -$892,058,256.68[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥30,375,904,765.21, an increase of 1.15% from ¥30,024,403,300.33 at the end of the previous year[8] - The total assets amount to ¥30,375,904,765.21, up from ¥30,029,364,092.71, showing growth in the company's asset base[27] - Non-current liabilities increased to ¥3,234,045,121.90 from ¥2,366,822,363.47, suggesting potential leverage for future investments[27] - The company's total liabilities stand at ¥13,611,603,933.92, compared to ¥13,478,456,807.24 in the previous period, indicating a slight increase in financial obligations[27] - Total liabilities increased to $13,478,456,807.24, up by $4,843,642.12[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 83,533, with the top ten shareholders holding 18.71% of the shares[17] - Xizang Huibang Technology Co., Ltd. holds 370,449,804 shares, representing 18.71% of the total shares, and has pledged 169,207,000 shares[17] - Zhang Songshan, a natural person, holds 117,095,583 shares, accounting for 5.91% of the total shares, with 57,140,000 shares pledged[17] Operational Metrics - Total operating revenue for the current period is ¥8,853,071,322.91, a decrease of 13.0% from ¥10,180,991,733.93 in the previous period[28] - Total operating costs for the current period are ¥7,857,544,207.71, down from ¥8,815,184,892.05, reflecting a cost reduction strategy[28] - The net profit margin is under pressure due to a decrease in operating revenue and an increase in sales expenses, which reached ¥1,021,485,264.52[28] - Research and development expenses increased to ¥325,832,813.94, compared to ¥286,550,552.75 in the previous period, indicating a focus on innovation[28] Liquidity and Cash Management - The company's cash and cash equivalents decreased from ¥4,186,619,295.37 to ¥3,982,678,887.21, reflecting a decrease in liquidity[21] - The company reported a decrease in cash and cash equivalents, impacting liquidity, with current assets totaling ¥11,192,759,675.35, down from ¥11,554,220,664.68[27] - The ending balance of cash and cash equivalents was $3,088,618,169.40, down from $3,520,862,118.20[36] - The net increase in cash and cash equivalents was $97,297,058.47, a significant decrease from $1,017,905,834.60 in the previous period[36] Accounting and Regulatory Changes - The company plans to adjust its accounting policies in response to new regulations effective from January 1, 2023, impacting deferred tax assets and liabilities[8] - Deferred tax assets increased to $342,078,600.61 from $337,117,808.23 due to the implementation of new accounting standards[37] Impairments and Losses - The company reported a significant impairment loss of ¥874,768.95, primarily due to inventory and fixed asset impairments[16] Audit Status - The company’s third-quarter report was not audited[38]

证券代码：002004 证券简称：华邦健康 公告编号：2023024 华邦生命健康股份有限公司 关于控股股东部分股份解除质押及质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于近日接到公司控股股东 西藏汇邦科技有限公司（以下简称"汇邦科技"）的通知，获悉其将所持有本公 司的部分股份办理解除质押及质押,具体情况如下： 二、本次质押基本情况 1 一、本次解除质押基本情况 股东 名称 是否为控股股东或第一 大股东及其一致行动人 本次解除质押 股份数量 （股） 占其所持股 份比例 占公司总股 本比例 质押起始日 解除质押日期 质权人 汇邦科技 是 23,700,000 6.40% 1.20% 2022.11.08 2023.10.26 五矿证券有限公 司 | 张一卓 | 55,060,000 | 2.78% | 20,100,000 | 36.51% | 1.02% | 0 | 0.00% | 0 | 0.00% | | --- | --- | --- | --- | --- | --- | --- | --- ...

1 证券代码：002004 证券简称：华邦健康 公告编号：2023023 华邦生命健康股份有限公司 关于控股股东部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于近日接到公司控股股东 西藏汇邦科技有限公司（以下简称"汇邦科技"）的通知，获悉其将所持有本公 司的部分股份办理质押展期手续,具体情况如下： 二、汇邦科技及其一致行动人股份累计质押基本情况 截至本公告披露日，汇邦科技及其一致行动人张松山先生、张一卓先生、赵 丹琳女士所持质押股份情况如下： | 股东名称 | 持股数量 | 持股比 | 累计质押数量 | 占其所持 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | （股） | 例 | （股） | 股份比例 | 总股本 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | | | | | 比例 | 限售和冻结 | 押股份 | 限售和冻结 ...

证券代码：002004 证券简称：华邦健康 公告编号：2023022 华邦生命健康股份有限公司 关于控股子公司山东凯盛新材料股份有限公司 向不特定对象发行可转换公司债券申请获得 中国证券监督管理委员会同意注册批复的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）控股子公司山东凯盛新材 料股份有限公司（以下简称"凯盛新材"）于近日收到中国证券监督管理委员会出 具的《关于同意山东凯盛新材料股份有限公司向不特定对象发行可转换公司债券 注册的批复》（证监许可﹝2023﹞1893 号），批复具体内容如下： 一、同意凯盛新材向不特定对象发行可转换公司债券的注册申请。 二、凯盛新材本次发行应严格按照报送深圳证券交易所的申报文件和发行方 案实施。 三、本批复自同意注册之日起 12 个月内有效。 四、自同意注册之日起至本次发行结束前，凯盛新材如发生重大事项，应及 时报告深圳证券交易所并按有关规定处理。 凯盛新材董事会将根据有关法律法规和批复文件的要求，在其股东大会授权 的范围内办理本次向不特定对象发行可转换公司债券的相关事宜，敬 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥5,868,718,925.46, a decrease of 12.40% compared to ¥6,699,663,435.01 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥387,144,741.66, down 30.86% from ¥559,915,559.98 in the previous year[22]. - The net cash flow from operating activities decreased by 53.99%, amounting to ¥249,048,807.80 compared to ¥541,238,737.12 in the same period last year[22]. - Basic earnings per share were ¥0.1955, reflecting a decline of 30.87% from ¥0.2828 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥377,173,488.57, a decrease of 32.37% from ¥557,705,491.22 in the same period last year[22]. - The company's total revenue for the reporting period was ¥5,868,718,925.46, a decrease of 12.40% compared to ¥6,699,663,435.01 in the same period last year[68]. - The revenue from the pharmaceutical industry increased by 4.82% to ¥1,568,016,956.29, accounting for 26.72% of total revenue[69]. - Revenue from the agrochemical new materials industry decreased by 29.73% to ¥3,320,431,062.53, representing 56.58% of total revenue[69]. - The company reported a net profit margin of 18% for the first half of 2023, an increase from 15% in the same period last year[120]. Assets and Liabilities - Total assets at the end of the reporting period were ¥30,427,589,050.92, representing a 1.33% increase from ¥30,024,403,300.33 at the end of the previous year[22]. - The total restricted assets at the end of the reporting period amounted to CNY 6,864,165,687.51, primarily due to pledged loans and guarantees[79]. - The total amount of external guarantees approved during the reporting period was 38 million yuan, with actual guarantees amounting to 34.5 million yuan[172]. - The total guarantee amount approved for subsidiaries during the reporting period was 565,925, with an actual guarantee amount of 384,477.06[175]. Research and Development - The company invested ¥222,535,452.13 in R&D, which is a 20.11% increase from ¥185,278,131.46 in the previous year[68]. - The company has developed 2 new class drugs and over 20 first research drugs, with 180 patents granted, including 3 international patents[52]. - The company has established a comprehensive drug development system covering raw materials, formulations, pharmacology, and clinical trials, with a focus on dermatological preparations[53]. - The company is actively promoting smart and green manufacturing, which has significantly improved product quality and production efficiency[46]. Market Expansion and Strategy - The company is expanding its overseas raw material drug market while consolidating its leading position in the prescription market domestically[31]. - The company is actively exploring the retail market to increase its market share outside of the prescription market, aiming to enhance product diversity and meet market demands[91]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[120]. - A strategic acquisition of a smaller biotech firm was completed, which is anticipated to enhance the company's R&D capabilities and add 150 million in annual revenue[120]. Environmental Compliance and Sustainability - The company is committed to environmental protection and safety management, implementing a comprehensive internal management system to address potential risks in production and operations[93]. - The company has established an environmental protection management department to ensure compliance with increasingly stringent environmental regulations in the chemical industry[96]. - The company has implemented measures to ensure that all emissions are within the regulatory limits, demonstrating commitment to environmental standards[114]. - The company has invested in complete environmental protection facilities to ensure compliance with legal requirements for pollutant disposal[141]. Operational Efficiency - The company has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in production costs by the end of 2023[120]. - The company has successfully reduced operational costs by 5% through efficiency improvements in the supply chain[177]. - The company is focusing on improving hotel quality and service to increase revenue while controlling operational costs in a competitive market[97]. Corporate Governance - The company reported a focus on customer-driven strategies, integrating production management, supply chain operations, and market sales to respond to client needs effectively[45]. - There were no changes in the board of directors, supervisors, or senior management during the reporting period[102]. - The annual shareholders' meeting had a participation rate of 26.97% and was held on May 17, 2023[101]. Community Engagement - The company provided financial assistance of 920,000 yuan for poverty alleviation and rural revitalization, benefiting over 7,650 people in Jiangsu, Jiangxi, and Shandong provinces[152].

单位：万元 非经营性资金 占用 资金占用方名称 占用方与上 市公司的关 联关系 上市公司核 算的会计科 目 2023 年期初 占用资金余 额 2023 年 1-6 月占用累计 发生金额 （不含利 息） 2023 年 1- 6 月占用资 金的利息 （如有） 2023 年 1- 6 月偿还 累计发生 金额 2023 年 6 月 30 日占 用资金余额 占用形成 原因 占用性质 控股股东、实 际控制人及其 附属企业 小计 - - - 前控股股东、 实际控制人及 其附属企业 小计 - - - 其他关联方及 附属企业 小计 总计 - - - 华邦生命健康股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 华邦生命健康股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 1/3 | | | | | | 2023 年 1-6 | | 2023 年 1- | 2023 年 | 1- | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其它关联资金 | ...

二、关联方资金占用情况 华邦生命健康股份有限公司独立董事 关于控股股东及其他关联方占用公司资金及对外担保情况 的专项说明及独立意见 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》、《深圳证券交易所股票上市规则》（以下简称《股票上市规则》） 相关法律、法规和《公司章程》相关规定，作为华邦生命健康股份有限公司（以 下简称"公司"）的独立董事，本着实事求是的原则，对公司对外担保情况和 2023 年半年度的关联方资金占用情况进行认真细致的核查，现发表如下专项说 明和独立意见： 一、对外担保情况 1、公司为全资及控股子公司担保情况 截止 2023 年 6 月 30 日，公司及控股子公司之间、子公司与子公司之间的实 际担保金额为 493,865.25 万元，占公司最近一期经审计的合并报表总资产的 16.45%，占公司最近一期经审计的合并报表净资产的 29.84%，占公司最近一期 经审计的合并报表归属于上市公司的净资产的 48.46%。 2、对外担保 公司分别于 2020 年 4 月 13 日、2020 年 5 月 15 日召开了第七届董事会第十 四次会议及 2019 年年度股东大会 ...

证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20230505 投资者关 系活动类 别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 参与单位 名称及人 员姓名 通过全景网"投资者关系互动平台"（网址：http://ir.p5w.net） 参与公司 2022 年度&2023 年一季报业绩说明会的投资者 时间 2023 年 5 月 5 日 (周五) 下午 15:00-17:00 地点 全景网"投资者关系互动平台"（网址：http://ir.p5w.net） 上市公司 接待人员 姓名 董事、总经理：张海安 董事、董事会秘书：彭云辉 独立董事：黎明 财务总监：王剑 投资者关 系活动主 要内容介 绍 1、在颖泰生物利润大幅下降的情况下，公司一季报利润能小幅 上涨，有点意外，请领导介绍一下一季报的利润来源，构成情况， 谢谢。 投资者您好，公司 2023 年一季报归母净利润与去年同期相比实 现增幅 5.1%，虽然颖泰生物本期利润出现大幅下降，但公司对颖泰 生物的持股比例 47.07%所受影响有限，同时，公司医药板块经营状 况良好，持 ...

Financial Performance - The company's operating revenue for the current period is CNY 2,975,546,798.68, a decrease of 12.46% compared to the same period last year[9]. - Net profit attributable to shareholders of the listed company is CNY 177,137,767.78, an increase of 5.05% year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 168,985,255.18, reflecting a 4.78% increase compared to the previous year[9]. - The net profit for the first quarter was 294,842,240.23 CNY, a decrease from 319,793,662.55 CNY in the previous year, representing a decline of approximately 7.3%[44]. - The total profit amounted to 366,979,165.37 CNY, down from 478,322,104.63 CNY, indicating a decrease of about 23.2% year-over-year[44]. - The company's operating profit was 373,052,903.14 CNY, compared to 479,840,467.75 CNY in the same period last year, reflecting a decline of approximately 22.2%[44]. - The basic earnings per share increased to 0.0895 CNY from 0.0852 CNY, showing a growth of about 2.7%[44]. Cash Flow - The net cash flow from operating activities shows a significant decline of 108.00%, with a current value of CNY -12,813,669.92[9]. - Net cash flow from operating activities turned negative at -¥12,813,669.92 compared to ¥160,139,339.82, a decline of 108.00% attributed to decreased sales volume[34]. - Cash inflow from investment activities totaled ¥2,619,725,609.42, an increase from ¥2,055,850,849.49 in the previous period[25]. - Cash outflow for investment activities was ¥2,667,219,986.51, significantly higher than ¥2,029,269,337.09 in the previous period[25]. - The company reported a net cash flow from financing activities of ¥271,341,170.39, compared to ¥41,768,134.81 in the previous period[25]. - The net cash outflow from financing activities was -7,096,160.62 CNY, an improvement compared to -143,352,411.67 CNY in the previous year[46]. - The total cash outflow from financing activities was 1,695,183,231.01 CNY, compared to 2,341,225,774.83 CNY in the previous year, reflecting a decrease of approximately 27.6%[46]. - The company reported a foreign exchange impact of -11,413,514.64 CNY on cash and cash equivalents, contrasting with a positive impact of 5,674,000.87 CNY in the previous year[46]. Assets and Liabilities - Total assets at the end of the reporting period amount to CNY 30,225,558,790.97, representing a 0.67% increase from the end of the previous year[9]. - Total liabilities amounted to ¥13,380,018,004.07, slightly down from ¥13,473,613,165.12 in the previous period[22]. - Shareholders' equity attributable to the listed company is CNY 10,368,342,116.43, up by 1.73% compared to the previous year[9]. - Total equity attributable to shareholders reached ¥10,368,342,116.43, up from ¥10,191,961,981.05 in the previous period[22]. - Deferred income increased to ¥305,678,087.18 from ¥278,214,493.71, indicating a growth of about 9.9%[22]. Investments and Subsidiaries - The company established a new subsidiary, Chongqing Songshan Membership Hospital Co., Ltd., with a registered capital of CNY 5 million, aiming to integrate medical resources[18]. - The company reported a decrease in trading financial assets by 32.53%, primarily due to the redemption of financial products during the reporting period[14]. - Investment income decreased significantly to ¥10,000,471.18 from ¥95,932,564.71, a decline of 89.58% due to reduced investment income from associated enterprises[34]. - Accounts receivable financing decreased by 30.14%, mainly due to a reduction in notes receivable[14]. - Contract liabilities decreased by 52.24%, attributed to the delivery of goods during the reporting period[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 89,791, with the largest shareholder, Tibet Huibang Technology Co., Ltd., holding 18.71%[34]. - The top ten shareholders include Tibet Huibang Technology Co., Ltd. (18.71%), Zhang Songshan (5.91%), and Dong Xiaoming (3.58%) among others[34]. Research and Development - Research and development expenses increased to ¥101,564,101.36 from ¥83,364,496.79, marking a growth of approximately 21.8%[22].

Product Development and Innovation - In 2022, the company launched over 10 functional skincare products, enhancing its "big skin" product matrix[4] - The company achieved approval for 1 formulation product and 7 active pharmaceutical ingredients for overseas certification[2] - The company has expanded its product offerings, including the approval of linezolid glucose injection (100ml, 300ml), enhancing its portfolio in skin, tuberculosis, and anti-tumor medications[67] - The company has launched over 10 functional products in the skin care segment, including ceramide essence oil and acne gel, leveraging 30 years of clinical experience in dermatology[67] - The company is focusing on high-value raw materials and key intermediates through collaboration with domestic and international research institutions[145] - The company is actively pursuing new product registrations in the oncology and digestive system medication fields, enhancing its product pipeline[121] - The company aims to develop 3-5 new pharmaceutical products annually and ensure rapid approval of in-progress products[144] - The company is developing new products in the lithium-ion battery electrolyte sector, expanding its downstream industry chain[122] Financial Performance - The company's operating revenue for 2022 was approximately ¥13.23 billion, representing a 6.45% increase compared to ¥12.43 billion in 2021[42] - The net profit attributable to shareholders decreased by 35.12% to approximately ¥433.28 million from ¥670.05 million in the previous year[42] - The net profit after deducting non-recurring gains and losses was approximately ¥408.65 million, down 32.77% from ¥610.11 million in 2021[42] - The net cash flow from operating activities increased by 89.65% to approximately ¥2.41 billion, compared to ¥1.27 billion in 2021[42] - The company reported a total distributable profit of RMB 780,260,536.94 for the reporting period[194] - The company achieved a revenue share of 13.80% from overseas sales in its main business, primarily exporting to large multinational companies such as DuPont and Toray[79] - The company reported a significant asset impairment loss of ¥560.36 million, representing 34.53% of total profit, which is not expected to be sustainable[126] Market Expansion and Strategy - The company aims to strengthen its leading position in the prescription market and expand its market share in the outpatient retail sector[3] - The company is focusing on expanding its market presence in the dermatology sector, which is expected to grow significantly due to increasing health awareness among consumers[54] - The company is actively pursuing market expansion in the OTC sector while strengthening its position in the prescription market[61] - The company has covered over 200,000 terminal points in the outpatient market, actively expanding its marketing channels beyond hospitals[69] - The company has partnered with over 10 online platforms, including Alibaba Health and Meituan, to enhance its e-commerce presence[69] - The company plans to open 20 new chain clinics nationwide, increasing the total to 50 clinics[148] Operational Efficiency and Production Capacity - The company’s raw material drug production bases in Changshou and Hanjing were officially put into operation, enhancing production capacity[7] - The company has established four major formulation production bases and three major raw material production bases, enhancing its supply chain stability and production efficiency[68] - The company invested over 3 billion RMB in production capacity expansion and digital transformation since 2015, significantly increasing production capabilities by 4-8 times at its main production bases[68] - The company is focusing on enhancing production efficiency to improve product competitiveness in the agricultural chemicals sector[57] - The company is committed to smart and green manufacturing to enhance product quality and expand production capacity[77] Research and Development - The company has a strong R&D team and core technologies in the production and purification of chlorosulfonic acid and acyl chloride products, ensuring a competitive edge[80] - The company has established a strong R&D infrastructure with four major centers and nearly 400 R&D personnel, supporting its drug development initiatives[94] - The company has a total of 45 authorized patents in the new materials sector, with 14 being invention patents, showcasing strong R&D capabilities[87] - R&D personnel increased by 8.10% to 1,281 in 2022, with the proportion of R&D staff rising to 10.08% of total employees[122] - The company is focusing on green and clean technology innovations in its production processes to enhance core competitiveness[121] Medical Services and Healthcare - The Beijing Huasheng Rehabilitation Hospital was approved for medical insurance qualifications, becoming a designated medical institution in Beijing[11] - The Chongqing Songshan Hospital served over 1.5 million patients, with the addition of 23 specialty outpatient clinics[10] - The company’s medical services are expected to continue growing, with a focus on innovative healthcare business models[9] - The company has established a comprehensive medical system that enhances collaboration among medical institutions, leveraging advanced technologies from the Swiss Basel Biotherapy Center to improve healthcare quality[98] Sustainability and Environmental Impact - The company has been recognized as a national "green factory" in the pharmaceutical industry, enhancing its sustainability credentials[7] - The company is committed to sustainable development and aims to become a comprehensive provider of agricultural chemical products globally[150] - The company has implemented a circular economy approach by utilizing sulfur dioxide separation and recycling, reducing production costs and environmental impact[103] - The company is addressing environmental policy risks by investing in environmental technology and establishing a risk-oriented internal management system[152] Governance and Compliance - The company adheres to legal and regulatory requirements for corporate governance, ensuring transparency and protection of investor rights[164] - The board of directors consists of 6 members, including 2 independent directors, ensuring compliance with governance standards[165] - The company has established specialized committees, including a strategy committee and an audit committee, to enhance decision-making processes[166] - The internal audit department operates independently and reports to the audit committee, ensuring effective internal control implementation[197] Tourism Business - The company operates three cable cars in the Yulong Snow Mountain Scenic Area and three in the Taibai Mountain National Forest Park, being the sole operator in these areas[83] - The company has a diverse tourism business model that includes cable car transport, scenic area transportation, hotel operations, and tourism performances[83] - The tourism service segment generated revenue of CNY 438,785,148.54, down 14.59% from the previous year[109] - The company faces intensified competition in the tourism market, particularly in the mid-to-high-end hotel sector due to the influx of international hotel brands[159]